Research programme: excitatory amino acid receptor modulators - Eli Lilly and Company
Alternative Names: LY-457691; LY-458545; LY-467711; LY-525327Latest Information Update: 27 Mar 2009
At a glance
- Originator Eli Lilly and Company; NPS Pharmaceuticals
- Class
- Mechanism of Action Excitatory amino acid agonists; Excitatory amino acid antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Neurological disorders; Pain
Most Recent Events
- 29 Nov 2000 The collaboration between Eli Lilly and Company and NPS Allelix has expired, giving Eli Lilly and Company full rights to the programme
- 30 Dec 1998 Eli Lilly and Company and NPS Allelix are collaborating on the development of compounds which target excitatory amino acid receptors
- 30 Dec 1998 Preclinical development for Neurological disorders in Canada (Unknown route)